Plain-English translation of NCT04830709 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →This study is following women with newly diagnosed advanced ovarian cancer as they receive their first course of treatment. Researchers want to understand how different maintenance therapies — including a medication called PARP inhibitor, bevacizumab, or no maintenance therapy — affect patients' outcomes, side effects, and quality of life in real-world medical practice in Germany.
Doctors now have several options for maintenance therapy after initial chemotherapy for ovarian cancer, but there is limited information about how these different approaches work in everyday clinical practice and how they affect patients' experiences, recovery, and long-term outcomes.
You will be assigned to one of three groups based on which maintenance therapy (if any) your doctor recommends: PARP inhibitor, bevacizumab, or no maintenance therapy. Throughout your treatment and recovery, you will share your medical information and report on your health experiences, side effects, and quality of life through electronic surveys. The study will follow you through your initial treatment phase and beyond to capture how the different approaches affect your outcomes and wellbeing.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Germany